Business
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a virtual R&D Day on Thursday, April 2, 2026 at 10:00 AM EDT. To register for the Akebia virtual R&D Day, click here. The event will feature scientific experts James A. Tumlin, MD (NephroNet), V. Michael Holers, MD (University of Colorado Anschutz) and Jonathan Barra
About this update from Akebia Therapeutics, Inc.
[{"type":"image","alt":"Akebia Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Akebia Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/865d2292021f9ae78a76043efeea8849"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qSd0MCVi23P15eWkfi6nEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MQ--/https://media.zenfs.com/en/globenewswire.com/865d2292021f9ae78a76043efeea8849","width":300,"height":122}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a virtual R&D Day on Thursday, April 2, 2026 at 10:00 AM EDT.","length":298,"tagName":"p"},{"type":"text","content":"To register for the Akebia virtual R&D Day, click here.","length":59,"tagName":"p"},{"type":"text","content":"The event will feature scientific experts James A. Tumlin, MD (NephroNet), V. Michael Holers, MD (University of Colorado Anschutz) and Jonathan Barratt, MD, PhD, FRCP (University of Leicester) who will join management to discuss Akebia’s robust pipeline of clinical stage kidney diseases programs:","length":297,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Praliciguat, a soluble guanylate cyclase stimulator currently in a Phase 2 clinical trial, targeting Focal Segmental Glomerulosclerosis (FSGS).","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"AKB-097, a next-generation tissue-targeted complement inhibitor planned to enter a Phase 2 basket trial in rare kidney diseases, including IgA nephropathy, lupus nephritis and C3 glomerulopathy, in the second half of 2026.","length":222,"tagName":"p"}]},{"val":[{"type":"text","content":"AKB-9090, a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor entering a Phase 1 clinical trial in acute kidney injury (AKI) associated with cardiac surgery, in the first half of 2026.","length":197,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":562,"olType":false},{"type":"text","content":"Company management and scientific experts will review the unmet need and current treatment landscape for these rare kidney diseases and discuss the mechanisms of acti...